foxh1 Antibody

What is the expected molecular weight of FOXH1 in Western blot applications?

FOXH1 has a calculated molecular weight of 39 kDa, but is typically observed at 40-44 kDa in experimental conditions . This discrepancy is common and may result from post-translational modifications, protein domain structure affecting SDS-PAGE migration, or species-specific variations. When performing Western blots, researchers should anticipate bands in the 40-44 kDa range rather than precisely at the calculated weight.

Which model organisms are suitable for FOXH1 antibody applications?

Based on available data, FOXH1 antibodies show reactivity with human, mouse, and rat samples . FOXH1 function has been extensively studied in:

• Xenopus: For examining germ layer specification and transcriptional repression functions

• Mouse: Particularly in embryonic stem cells for chromatin regulation studies

• Human: In cell reprogramming contexts affecting epithelial-mesenchymal transitions

The conservation of epitopes across these species makes FOXH1 antibodies valuable tools for comparative developmental studies.

What is the optimal fixation protocol for FOXH1 immunofluorescence studies?

For successful FOXH1 immunofluorescence, the following protocol is recommended:

• Fix samples in 4% paraformaldehyde for 10 minutes at room temperature

• Permeabilize with 0.5% Triton X-100 in PBS for 5 minutes

• Block with 0.1% Tween-20 and 2% Goat Serum for 1 hour

• Incubate with primary FOXH1 antibody (1:200 dilution) for 1 hour

• Wash three times with TBST

• Incubate with appropriate secondary antibody (e.g., AlexaFluor488)

• Counterstain nuclei with Hoechst

This protocol optimizes nuclear signal detection while minimizing background.

How should I design ChIP-seq experiments to study dynamic FOXH1 binding during development?

For optimal ChIP-seq analysis of FOXH1's developmental dynamics:

• Temporal sampling strategy:

  • Collect samples at specific developmental stages (e.g., early blastula, late blastula, early gastrula)

  • Use at least two independent biological replicates per timepoint

• Technical considerations:

  • Apply 'irreproducibility discovery rate' (IDR) analysis to identify high-confidence peaks

  • Perform pairwise Pearson correlation analyses to verify inter-stage variance exceeds intra-stage variance

• Integrative analysis:

  • Compare FOXH1 binding with co-factors (e.g., Smad2/3)

  • Correlate binding data with RNA-seq to link binding events with transcriptional outcomes

This approach has successfully identified thousands of bound regions that change dynamically during development, revealing FOXH1's role in marking developmental genes before activation .

How can I distinguish between FOXH1's activator and repressor functions using antibody-based approaches?

FOXH1 exhibits context-dependent activator and repressor functions that can be distinguished through:

• Co-factor analysis:

  • ChIP for FOXH1 alongside co-activators (Smad2/3) or co-repressors (HDAC1, TLE/Groucho)

  • Sequential ChIP (ChIP-reChIP) to identify regions where FOXH1 and specific co-factors co-occupy

• Chromatin state correlation:

  • Associate FOXH1 binding with activating (H3K27ac, H3K4me1/2) or repressive (H3K27me3) histone marks

  • Integrate ATAC-seq data to correlate FOXH1 binding with chromatin accessibility changes

• Functional validation:

  • Compare gene expression in FOXH1 knockdown/overexpression contexts across different tissues

  • In Xenopus, FOXH1 represses mesendodermal genes in ectoderm through Hdac1 interaction

What controls are essential for validating FOXH1 antibody specificity in developmental studies?

To ensure rigorous validation of FOXH1 antibody specificity:

• Genetic controls:

  • Compare antibody signal in wild-type versus FOXH1 knockdown samples (e.g., using morpholinos)

  • Perform rescue experiments with morpholino-resistant FOXH1 mRNA to restore signal

• Biochemical validation:

  • Confirm single band at expected molecular weight (40-44 kDa) in Western blot

  • Perform peptide competition assays to block specific binding

• Cross-species validation:

  • Test antibody performance across species with known FOXH1 conservation

  • Compare signal in tissues with differential FOXH1 expression

• Experimental context:

  • Include positive control tissues known to express FOXH1 (e.g., mouse liver tissue, L02 cells)

  • Use sample-dependent optimization of antibody dilution (1:200-1:1000 for Western blot)

These validation steps ensure reliable results in developmental studies where FOXH1 expression patterns change dynamically.

Why do I observe multiple bands when using FOXH1 antibodies in Western blot experiments?

Multiple bands in FOXH1 Western blots may result from several factors:

• Biological factors:

  • Isoforms or splice variants with different molecular weights

  • Post-translational modifications (especially phosphorylation)

  • Proteolytic degradation during sample preparation

• Technical considerations:

  • Cross-reactivity with related Fox family proteins

  • Incomplete denaturation affecting protein migration

  • Non-specific binding due to suboptimal blocking or antibody concentration

To address this issue:

• Compare results with expected 40-44 kDa band for FOXH1

• Include positive control samples (mouse liver tissue, L02 cells)

• Optimize blocking conditions and antibody dilution

• Consider phosphatase treatment to determine if higher molecular weight bands are phosphorylated forms

How should I interpret changes in FOXH1 binding patterns across developmental timepoints?

When analyzing dynamic FOXH1 binding during development:

• Quantitative assessment:

  • Use pairwise Pearson correlation analyses to compare binding between stages

  • Apply clustering analysis to group binding sites by temporal patterns

• Functional correlation:

  • Early blastula FOXH1 binding correlates with TLE co-repressor presence

  • Changes in binding often reflect transitions in developmental programming

• Mechanistic insights:

  • Early binding (before zygotic genome activation) suggests pioneering activity

  • Sequential binding of FOXH1 followed by other factors (e.g., Smad2/3) indicates hierarchical regulation

  • Co-occupancy with HDAC1 in specific contexts suggests repressive function

• Target gene analysis:

  • Connect dynamic binding sites to developmental gene expression patterns

  • Perform gene ontology analysis on stage-specific FOXH1 targets

These interpretative approaches reveal FOXH1's role in marking developmental genes for later activation or repression.

What explains the discrepancy between predicted and observed molecular weight for FOXH1?

The observed 40-44 kDa molecular weight versus the calculated 39 kDa can be explained by:

• Post-translational modifications:

  • Phosphorylation (common for transcription factors) adds approximately 1-2 kDa per modification

  • Other modifications like acetylation or methylation may affect migration

• Structural considerations:

  • The forkhead domain structure may alter migration in SDS-PAGE

  • Incomplete denaturation of structured domains

• Technical factors:

  • Gel concentration affecting migration rates

  • Buffer composition and running conditions

  • Molecular weight marker calibration

To address this discrepancy:

• Use molecular weight markers spanning 30-50 kDa range

• Include known positive controls

• Consider phosphatase treatment to determine contribution of phosphorylation

• If necessary, confirm protein identity via mass spectrometry

How does FOXH1 binding compare to other Fox family transcription factors?

Fox family members display distinct binding patterns despite their conserved DNA-binding domains:

• Binding divergence:

  • When expressed in the same cellular context (e.g., mES cells), Fox family members (FOXA1, FOXL2, FOXG1, FOXP3, FOXC1) show highly divergent genomic binding distributions

  • For example, 96% of FOXL2 binding sites show greater enrichment for FOXL2 than FOXA1

• Chromatin state preferences:

  • FOXP3 and FOXG1 predominantly bind regions already enriched for accessibility markers or active histone modifications

  • FOXL2 and FOXC1 bind regions lacking these marks

  • FOXA1 shows intermediate association with preexisting regulatory elements

• Predictive features:

  • DNA sequence alone is insufficient to predict binding patterns

  • Combined CNN models incorporating both sequence and chromatin features better predict Fox factor binding specificity

This comparative analysis provides insights into the unique functions of FOXH1 versus other Fox family members in development and cell fate specification.

How can I use FOXH1 antibodies to study its interactions with chromatin regulators?

To investigate FOXH1's interactions with epigenetic modifiers like PRC2 and HDAC1 :

• Co-immunoprecipitation approaches:

  • Immunoprecipitate with FOXH1 antibody and blot for interaction partners (EZH2, EED, SUZ12, HDAC1)

  • Perform reciprocal IP with antibodies against putative partners

  • Include benzonase treatment (100 units per sample) to determine if interactions are DNA-dependent

  • Use ethidium bromide titration (50-400 ng/μl) to disrupt DNA-mediated interactions

• Sequential ChIP analysis:

  • Perform ChIP-reChIP to identify genomic regions where FOXH1 co-occupies with chromatin regulators

  • Compare binding profiles (as shown for FOXH1 and HDAC1 in Figure 3E )

• Functional validation:

  • Correlate binding with histone modification changes (H3K27me3 for PRC2, hypoacetylation for HDAC1)

  • Analyze expression of co-bound genes in control versus FOXH1 or HDAC1 knockdown contexts

These approaches revealed that FOXH1 and HDAC1 co-repress mesendodermal genes in Xenopus ectoderm, with 11 of 12 identified co-repressed genes showing enriched expression in either mesoderm or endoderm .

What role does FOXH1 play as a pioneer factor and how can this be studied?

FOXH1 functions as a pioneer transcription factor that can access condensed chromatin:

• Experimental approaches:

  • ChIP-seq time course analysis reveals FOXH1 binding to enhancers before zygotic genome activation

  • Correlation of early FOXH1 binding with subsequent recruitment of other factors and RNA polymerase II

• Chromatin state analysis:

  • Compare FOXH1 binding sites with ATAC-seq data and histone modifications

  • Identify sites where FOXH1 binding precedes changes in chromatin accessibility

  • Study FOXH1 binding to cis-regulatory modules prior to dynamic transcription

• Mechanistic insights:

  • FOXH1 occupies enhancers of mesendodermal genes in early cleavage stages (32-cell)

  • Early blastula FOXH1 binding correlates with TLE co-repressor presence

  • FOXH1 marks developmental genes for later activation by other factors

These pioneering activities place FOXH1 at the top of a hierarchy of interactions in developmental gene regulation, marking genes for subsequent activation or repression .

How can FOXH1 antibodies be used to study its role in cellular reprogramming?

FOXH1 has significant functions in cellular reprogramming that can be investigated using antibodies:

• Role in reprogramming:

  • FOXH1 enhances epithelial marker expression and suppresses mesenchymal gene expression during OSKM-mediated human cell reprogramming

  • Inhibiting FOXH1 halts iPSC colony formation and blocks generation of TRA-1-60+ colonies

• Experimental approaches:

  • Western blot analysis of FOXH1 levels during different reprogramming stages

  • ChIP-seq to identify FOXH1 binding sites in somatic cells versus partially reprogrammed cells

  • Co-IP to identify reprogramming-specific interaction partners

• Functional validation:

  • Combine FOXH1 knockdown/overexpression with assessment of reprogramming markers

  • FOXH1 overexpression significantly reduces expression of epithelial markers (E-CAD, EPCAM, OCLN) and mesenchymal markers (SNAI2, TWIST1)

These studies provide insights into FOXH1's complex role in cellular plasticity and cell fate transitions beyond embryonic development.

What methodological considerations are important when designing experiments to study FOXH1 in different developmental contexts?

When investigating FOXH1 across developmental contexts:

• Species-specific considerations:

  • Optimize antibody dilutions for each species (human, mouse, Xenopus)

  • Consider differences in FOXH1 expression patterns (ubiquitous in early Xenopus embryos )

• Tissue isolation techniques:

  • For Xenopus studies, carefully dissect specific regions (animal cap for ectoderm)

  • Precisely stage embryos to capture dynamic expression patterns

• Context-dependent function analysis:

  • In Xenopus ectoderm, FOXH1 functions as a repressor of mesendodermal genes

  • In mesendoderm, FOXH1 may function as an activator with Nodal signaling

• Combinatorial TF analysis:

  • FOXH1 functions in combination with other TFs like Otx1, Vegt, Sox3, and Sox7

  • Consider co-immunoprecipitation or sequential ChIP to identify context-specific co-factors

These methodological considerations enable comprehensive understanding of FOXH1's diverse functions across developmental contexts and species.